Cargando…

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity

AIMS: Inflammatory biomarkers, including CRP, the neutrophil‐to‐lymphocyte ratio (NLR), and the neutrophil‐to‐eosinophil ratio (NER), may predict outcomes in cancer. However, their value in immune checkpoint inhibitor (ICI) therapy‐associated cardiotoxicity remains elusive. We aimed to characterize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Lin, Cui, Chanjuan, Lv, Dan, Li, Yiqun, Huang, Liyan, Feng, Jiayu, An, Tao, Tian, Pengchao, Yang, Ke, Hu, Linjun, Gao, Lizhen, Zhang, Jian, Zhang, Yuhui, Ma, Fei, Wang, Yanfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192297/ https://www.ncbi.nlm.nih.gov/pubmed/36987542 http://dx.doi.org/10.1002/ehf2.14340

Ejemplares similares

Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
por: Li, Yiqun, et al.
Publicado: (2022)

sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure
por: Chen, Yuyi, et al.
Publicado: (2023)

Cardiotoxicity of immune checkpoint inhibitors
por: Varricchi, Gilda, et al.
Publicado: (2017)

Cardiotoxicity of Immune Checkpoint Inhibitors
por: Patel, Rushin P., et al.
Publicado: (2021)

Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients: Ready for Prime Time?
por: Aras, Mandar A., et al.
Publicado: (2020)

Big Endothelin-1 as a Predictor of Reverse Remodeling and Prognosis in Dilated Cardiomyopathy
por: Feng, Jiayu, et al.
Publicado: (2023)

Cardiotoxicity from immune checkpoint inhibitors
por: Michel, Lars, et al.
Publicado: (2019)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
por: Nardi Agmon, Inbar, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
por: Li, Chenghui, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists
por: Liu, Binliang, et al.
Publicado: (2022)

Managing cardiotoxicity associated with immune checkpoint inhibitors
por: Upadhrasta, Sireesha, et al.
Publicado: (2019)

Cardiotoxicity risk factors with immune checkpoint inhibitors
por: Brumberger, Zachary L., et al.
Publicado: (2022)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
por: Li, Xiang, et al.
Publicado: (2023)

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
por: Guo, Xiaoxiao, et al.
Publicado: (2019)

Prognostic value of RDW alone and in combination with NT‐proBNP in patients with heart failure
por: Liang, Lin, et al.
Publicado: (2022)

Prognostic value of high‐sensitivity cardiac troponin I in patients with non‐ischaemic heart failure: insights from China
por: Tian, Pengchao, et al.
Publicado: (2022)

Predictive value of remnant cholesterol level for all-cause mortality in heart failure patients
por: Zhao, Lang, et al.
Publicado: (2023)

Biomarkers of Uremic Cardiotoxicity
por: Stopic, Bojan, et al.
Publicado: (2021)

Incorporating inflammatory biomarkers into a prognostic risk score in patients with non-ischemic heart failure: a machine learning approach
por: Feng, Jiayu, et al.
Publicado: (2023)

Respiratory system toxicity induced by immune checkpoint inhibitors: A real-world study based on the FDA adverse event reporting system database
por: Cui, Chanjuan, et al.
Publicado: (2022)

Clinical Profile, Treatment, and Prognosis of Left Ventricular Thrombus in Dilated Cardiomyopathy
por: Huang, Liyan, et al.
Publicado: (2023)

Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022
por: Wang, Yanfeng, et al.
Publicado: (2023)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
por: Mascolo, Annamaria, et al.
Publicado: (2021)

Machine Learning for Mortality Prediction in Patients With Heart Failure With Mildly Reduced Ejection Fraction
por: Tian, Pengchao, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies
por: Xu, Shirley, et al.
Publicado: (2021)

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
por: Ronen, Daniel, et al.
Publicado: (2022)

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors
por: Esposito, Roberta, et al.
Publicado: (2021)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis
por: Liu, Maobai, et al.
Publicado: (2022)

Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity score‐matched analysis
por: Cui, Chanjuan, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Clinical characteristics of patients with heart failure and intracardiac thrombus
por: Zhai, Mei, et al.
Publicado: (2022)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
por: Zheng, Fei, et al.
Publicado: (2023)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qauspbqatlmqgjd2ohlt41uj1i